Living up to the hype around GLP-1 obesity treatments is tough enough. But Eli Lilly needs to hit its own targets.
Category: Uncategorized
Bitcoin treasury pioneer MicroStrategy rebrands with a new name: Strategy
The software company turned “bitcoin development” firm unveiled a new name and logo ahead of its fourth-quarter earnings.
JPMorgan says these stocks are the most at risk from Trump’s ongoing tariff battles
In an effort to navigate “trade turbulence,” JPMorgan listed several U.S. companies that the firm believes will likely be sensitive to escalating tariffs.
How to bet on an AMD comeback with options using a ‘recovery trade’
Mike Khouw breaks down how investors can bet on AMD comeback without risking as much capital as going long the stock.
What that charts say is next for the U.S. dollar and how that could help stocks
Frank Cappelleri breaks down the charts on the U.S. dollar and how it correlates to the S&P 500.
A way to get long an AI play while keeping a margin of safety in case there’s more volatility
Tony Zhang describes a cash-secured put strategy on Lam Research.
JPMorgan picks the stock winners and losers after cheap DeepSeek upends AI trade
JPMorgan highlighted cloud storage firm Snowflake and semiconductor manufacturer Broadcom as potential DeepSeek beneficiaries.
Wall Street sees a buying opportunity in Chipotle pullback
Shares in the burrito chain fell after Chipotle’s full-year financial guidance disappointed investors.
Stocks that split double the market’s return. Bank of America names who’s next
Jared Woodard of Bank of America Securities pointed out that companies are splitting their stock at a pace that hasn’t been seen in more than ten years in recent months.
Leerink upgrades this beaten-down biotech stock, says investors should buy the dip
Analyst David Risinger upgraded shares to outperform. He also raised his price target to $834 from $762.